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Abstract
Background: Genetic factors play a major role in the risk for neurodevelopmental disorders such as autism
spectrum disorders (ASDs) and intellectual disability (ID). The underlying genetic factors have become better
understood in recent years due to advancements in next generation sequencing. These studies have uncovered a
vast number of genes that are impacted by different types of mutations (e.g., de novo, missense, truncation, copy
number variations).
Abstract: Given the large volume of genetic data, analyzing each gene on its own is not a feasible approach and
will take years to complete, let alone attempt to use the information to develop novel therapeutics. To make sense
of independent genomic data, one approach is to determine whether multiple risk genes function in common
signaling pathways that identify signaling “hubs” where risk genes converge. This approach has led to multiple
pathways being implicated, such as synaptic signaling, chromatin remodeling, alternative splicing, and protein
translation, among many others. In this review, we analyze recent and historical evidence indicating that multiple
risk genes, including genes denoted as high-confidence and likely causal, are part of the Wingless (Wnt signaling)
pathway. In the brain, Wnt signaling is an evolutionarily conserved pathway that plays an instrumental role in
developing neural circuits and adult brain function.
Conclusions: We will also review evidence that pharmacological therapies and genetic mouse models further
identify abnormal Wnt signaling, particularly at the synapse, as being disrupted in ASDs and contributing to disease
pathology.
Keywords: Autism spectrum disorders, ASD, Synapse, Wnt signaling, GSK3, Neurodevelopment, Signaling, Plasticity,
Mutations, Neurotransmission, Neurogenesis, Neuronal migration
Background
The emerging genetic landscape of Wnt signaling in ASDs
ASDs and other psychiatric disorders may have heritabil-
ity estimates greater than 90% [1], suggesting a strong
genetic component to disease. With this background in
mind, there has been an enormous advancement of new
genetic technologies to discover risk-causing genes and
loci. These developments paired with an increased ability
to process large data sets have led to many new risk
genes being discovered. The number of genes and
chromosomal loci linked to ASDs is growing, making it
difficult to determine which one(s) to study. This has in-
spired the field to determine if there are links between
the genes and whether they converge into signaling
networks important for proper brain development.
While the spectrum of ASDs is reflected by the multiple
individual risk genes and loci, there is some common de-
nominator between affected individuals, which strongly
suggests that disruption of the core neurodevelopmental
signaling pathways leads to disease symptoms. In this re-
view, we will examine accumulating evidence for the in-
volvement of Wnt signaling in developmental cognitive
disorders. This includes emerging genetic data from
large sequencing studies, clinically used medications,
and mouse models. We will also present potential ave-
nues for therapeutic approaches, and how Wnt signaling
may be modulated for treatment of patient symptoms by
leveraging clinical trial data from other fields.
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Making sense of genetic findings
It is no surprise that the clinical heterogeneity of ASDs
can be explained, at least in part, by the large number of
genetic mutations found through next-generation se-
quencing. The number of mutations discovered ranges
in the several hundreds, according to well-known
sources such as the Simons Foundation Autism Research
Initiative (SFARI). There is much difficulty in trying to
understand the biological etiology of ASDs when so
many genes are involved. One hypothesis is that the gen-
etic lesions disrupt specific signaling pathways during
discrete time points of brain development. For example,
many of the initial genetic studies identified genes in-
volved in synapse development and refinement. This was
largely based on findings that multiple genes in syn-
dromic forms of ASDs (e.g., Fragile X syndrome (FMR1),
Rett syndrome (MECP2), Angelman syndrome (UBE3A),
and genes that cause non-syndromic forms of ASDs
(e.g., the Shank and neuroligin/neurexin family of pro-
teins) have important roles during synapse development
and refinement [2–8]. This suggests that the disruption
of postnatal synaptic maturation could increase the risk
for developing ASDs and related disorders. However,
there has been accumulating evidence that other brain
developmental milestones are also vulnerable, such as
prenatal brain development (e.g., neurogenesis) [9], or
postnatal development of non-neuronal cells (e.g., oligo-
dendrocytes during myelination and microglia function)
[10–13]. This is also supported by the implication of
discrete cell types in the brain based on the identifica-
tion of specific risk genes expressed in those cells (e.g.,
inhibitory neurons) [14–16]. In the current review, we
take an alternative approach that is not in contrast to
these hypotheses but examines whether there is conver-
gence of multiple risk genes onto specific signaling path-
ways, which ultimately impact multiple cell types and/or
developmental processes. We put forth the notion that
by focusing on a specific pathway and dissecting which
molecular players in that pathway are important for dis-
ease pathophysiology, it may offer an opportunity to
identify key proteins to be pharmacologically targeted by
drug therapies to treat these disorders.
Review
Convergent evidence for Wnt signaling
One pathway highlighted in the multitude of genetic
studies is the Wingless (Wnt) signaling. This pathway is
highly studied and conserved from lower to higher or-
ganisms, where it plays a variety of roles in almost all
tissues. Broadly speaking, Wnt signaling in the brain can
be divided into two main pathways: (i) “canonical” sig-
naling that results in the stabilization of the protein β-
catenin (encoded by CTNNB1), which upon stabilization,
can exert functions at the plasma membrane or in the
nucleus and can act as a transcription factor that modu-
lates the expression of target genes (Fig. 1); and (ii)
“non-canonical” β-catenin-independent signaling [17].
Interestingly, many of the proteins in both signaling
pathways localize to the synapse and play important
functions in synaptic growth and maturation [18–23].
There are now multiple lines of evidence implicating this
pathway in the etiology and pathophysiology of ASD and
intellectual disability (ID). While the human genetic data
is an important supporting factor, it is not the only one.
There are a number of mouse genetic knockout (KO)
models targeting Wnt signaling molecules, describing
molecular, cellular, electrophysiological, and behavioral
deficits that are consistent with ASD and ID. Further-
more, the genes involved in Wnt signaling are of signifi-
cant clinical interest because there are a variety of
approved drugs that either inhibit or stimulate this
pathway.
Genetic evidence implicating Wnt signaling genes and
support by cellular models
CHD8
The strongest single candidate gene for non-syndromic
ASDs is chromodomain helicase DNA binding protein 8
(CHD8) [24–30]. There are multiple de novo, truncating,
or missense mutations discovered in CHD8 in individ-
uals with ASDs [27–29, 31–34]. CHD8 is found at active
transcription sites with histone modifications H3K4me3
or H3K27ac, and it is thought to directly activate genes
by binding near the transcriptional start site and pro-
moting transcription factor activity or recruitment. It
can also indirectly impact transcription by interacting
with modified histone sites and other co-regulators to
make chromatin more assessable [24, 34–36]. Interest-
ingly, one of the major pathways regulated by CHD8 is
canonical Wnt signaling [37, 38]. Previous work charac-
terized CHD8 as a negative regulator of canonical Wnt
signaling, which fits with the hypothesis that elevated ca-
nonical Wnt signaling activity causes excessive prolifera-
tion of embryonic neural progenitor cells (NPCs) in the
brain and may in part explain the macrocephaly (“big
brain”) phenotype observed in patients [27]. Further-
more, recent studies in human neural progenitors lack-
ing one copy of CHD8 support this notion, as it revealed
many target genes controlled by CHD8 that are involved
in the regulation of spine head size [34, 39, 40]. However
a recent study discovered that CHD8 is in fact a positive
regulator of Wnt/β-catenin signaling NPCs, while simul-
taneously demonstrating that it negatively regulates the
pathway in non-neuronal cell lines [41]. Given this unex-
pected finding, this suggests that CHD8 regulates Wnt
signaling in a cell-specific manner, and the possibility
that some of the CHD8 mutations may not be as simple
as loss-of-function for Wnt signaling. Further work is
Kwan et al. Journal of Neurodevelopmental Disorders  (2016) 8:45 Page 2 of 10
needed to clarify how CHD8 regulates Wnt signaling in
different cell types in the brain, and how patients with
CHD8 mutations acquire macrocephaly. It is also im-
portant to note that Wnt signaling is only one neurode-
velopmental pathway regulated by CHD8, and recent
studies have identified many others (e.g., chromatin re-
modeling). Therefore, future work needs to determine
the precise mechanisms and time points during which
CHD8 regulates Wnt signaling during neurodevelop-
ment. This is important to better comprehend how pre-
natal brain development could be compromised in
individuals with CHD8 mutations.
CTNNB1 (β-catenin)
β-catenin is a central player in the canonical Wnt signal-
ing pathway and works with co-factors to initiate Wnt-
dependent gene transcription (Fig. 1). It has directly
been implicated in ASDs due to the identification of de
novo mutations in the CTNNB1 gene in patients with
ASD using exome sequencing [25, 28, 29, 42]. Given the
core nature of this gene in canonical Wnt signaling, this
strongly places aberrations in Wnt signaling as one of
the main networks in ASD pathogenesis. Network ana-
lysis from gene expression data also indicates that β-
catenin exists in a protein network, including CHD8 and
other ASD or ID associated genes [25]. The relationship
between Wnt signaling and chromatin remodeling fac-
tors demonstrates that proper interplay between these
pathways is important for appropriate levels of canonical
Wnt-dependent gene transcription. CHD8 regulates β-
catenin-mediated canonical Wnt signaling, which could
occur by CHD8 directly by binding to β-catenin or indir-
ectly by inhibiting the recruitment of co-factors required
for transcription at promoter sequences. Future work
will need to determine precisely which neural progenitor
sub-populations are most sensitive to disruptions in ca-
nonical Wnt/β-catenin signaling during prenatal brain
development. For example, previous studies indicated
that global stabilization of β-catenin in the cortex, which
elevates canonical Wnt signaling, leads to brain over-
growth due to increased cycling neural progenitor cells
and production of neurons [43]. In contrast, deletion of
β-catenin from parvalbumin-expressing inhibitory neu-
rons leads to ASD-like defects in neuronal activation
and behavior, such as social interaction and object rec-
ognition impairments [44].
β-caxtenin also functions in pathways other than ca-
nonical Wnt signaling, such as cell adhesion at the
Fig. 1 Summary of genetic and pharmacological evidence implicating Wnt signaling in developmental cognitive disorders. This diagram depicts the
canonical Wnt signaling pathway which consists of Wnt binding to the Frizzled-LRP5/6 co-receptor complex and inhibiting the disassembly of the
destruction complex which results in stabilized β-catenin levels, translocation to the nucleus, and initiation of Wnt-dependent gene transcription. Several
genes in the canonical Wnt pathway are also identified as high-risk genes associated with autism and intellectual disability (CHD8, DDX3X, and TCF4).
Furthermore, listed are a number of pharmacological agents and drugs that target Wnt signaling molecules and can modulate the pathway. Many of the
genes listed are shared between different upstream ligand-receptor pathways
Kwan et al. Journal of Neurodevelopmental Disorders  (2016) 8:45 Page 3 of 10
plasma membrane. β-catenin interacts with cadherins to
regulate dendritic spine growth and synaptic competition
during the process of postnatal period of dendritic prun-
ing [45]. A recent study identified that dominant muta-
tions in CTNNB1 from ID patients when expressed in
mice have a reduced affinity for membrane-associated
cadherins [46]. This is associated with a decrease in cad-
herin interaction and decreased intrahemispheric connec-
tions, with deficits in dendritic branching, long-term
potentiation, and cognitive function [46]. Therefore, it is
possible that mutations in β-catenin could lead to aberrant
Wnt signaling developmentally, concurrent with disrup-
tion of plasma membrane signaling at synaptic sites, both
leading to disrupted gene transcription programs and ab-
normal synaptic plasticity. Furthermore, both of these
pathogenic events would increase disease risk. In this re-
gard, these pathways are also likely connected given that
β-catenin signaling at the membrane impacts nuclear
Wnt-dependent transcription [47].
PTEN
Another high-risk autism candidate gene that has
roles in Wnt signaling is PTEN due to the discovery
of numerous individuals with mutations [29, 48–50].
PTEN has multiple functions but is best known for
its role as a negative regulator of the PI3K-Akt-
mTOR pathway. Individuals with heterozygous muta-
tions in PTEN are also at risk for macrocephaly, in-
dicating that PTEN regulates brain size, which is
thought to be an impact on certain individuals with
ASD [51–59]. Multiple mouse models of Pten have
further strengthened the notion that it is an import-
ant regulator of different neural circuits associated
with ASDs and cognition. For example, an early study
identified that global Pten +/- mice have impairments
in social interaction behaviors [52]. Knocking out
Pten in the cerebellar Purkinje cells led to impaired
sociability, repetitive behavior, and deficits in motor
learning. Additionally, knocking out Pten in a subset
of cortical excitatory neurons results in profound
synaptic signaling changes [60], while ASD-associated
Pten alleles expressed in inhibitory neurons cause
excitatory/inhibitory imbalances [54]. Interestingly,
PTEN has recently been identified to function with
β-catenin to regulate normal brain growth, implicating
PTEN in Wnt signaling. It was discovered that
β-catenin signaling is elevated in a mouse model of
Pten (Pten +/-), and a heterozygous mutation in β-catenin
suppresses the excessive cortical brain growth in Pten +/-
mice [53]. This indicates that multiple ASD risk factors
likely converge upon neural progenitor proliferation dur-
ing embryonic brain development, potentially through
regulation of canonical Wnt signaling.
TCF7L2 (TCF4)
Recent studies have identified mutations in CTNNB1
within individuals with developmental delay and ID who
do not have an ASD [46, 61, 62]. Additional support
comes from another ASD exome sequencing study that
identified de novo loss of function variants in TCF7L2
(transcription factor 7-like 2 (T-cell specific, HMG-box))
[63, 64], which also goes by the name TCF4, and is con-
fused with transcription factor 4 (TCF4) as they share
the same symbol. Importantly, TCF7L2 is a key player in
canonical Wnt signaling as it helps to initiate gene tran-
scriptional response when Wnt ligands bind their recep-
tors on the membrane, and the signal is transduced to
the nucleus (Fig. 1). These genetic studies directly impli-
cate de novo missense variants in TCF4 in ASD, suggest-
ing that perturbations to the core canonical signaling
complex play a pathogenic role. However, the role of
TCF4 in brain development and which time points and
cell types it regulates is not well known and needs to be
identified in future studies.
DDX3X
A recent study identified de novo mutations in DEAD-
box helicase 3, X-linked (DDX3X) in a population of un-
explained ID [65]. DDX3X was identified as a regulator
of the Wnt-β-catenin network, via regulation of the kin-
ase activity of CK1ε, to promote phosphorylation of Dvl,
both critical factors in canonical Wnt signaling (Fig. 1).
Moreover, in model systems testing the Wnt pathway,
DDX3X was found to be required for Wnt-β-catenin sig-
naling in mammalian cells through loss of function stud-
ies [66]. Therefore, in addition to ASD, Wnt-β-catenin
signaling may be disrupted in generalized ID and devel-
opmental disorders (DD), further demonstrating the im-
portance of this pathway in proper neurodevelopment.
However, a critical question that remains is how do mu-
tations in Wnt signaling molecules give rise to different
phenotypes, such as ASD versus ID/DD? This insight
would provide tremendous clinical utility, as it will allow
caregivers and clinicians to plan therapies according to
the future outcome.
Animal models support the involvement of Wnt signaling
Mouse models provide support for Wnt signaling as a
clinically relevant pathway for developmental cognitive
disorders. First, modeling of high-risk (i.e., causative)
ASD genes, for example using gene knockouts (KO),
offer the opportunity to determine the neural circuits
and brain regions responsible for causing ASD-like
behavior. Second, interrogation of other genes in the
same pathway, which are not directly involved in ASD
from human genetic studies, offers the opportunity to
further support that pathway in ASD pathophysiology.
For example, while no ASD-specific genetic mutations
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have been identified in the disheveled genes (Dvl 1, 2
and 3), Dvl1 or Dvl1/3 KO mice display adult social and
repetitive behavioral abnormalities, which are the core
features of ASD symptoms [67–69]. This type of ex-
ample lends further evidence that perturbation of the
core Wnt signaling transduction molecules like Dvl1/3
can result in ASD-like abnormalities even though they
are not directly implicated in human genetic studies.
In addition to Dvl1/3, recent studies have highlighted
that conditional or complete KO mouse models of other
genes involved in Wnt signaling support the pathway be-
ing involved in ASD-like phenotypes. One of the best-
studied genes is glycogen synthase kinase 3 (GSK3) α and
β, which is a negative regulator of canonical Wnt signal-
ing and also plays important roles directly at the synapse
(Fig. 1). It is well-established that the inhibition of GSK3
using lithium or specific inhibitors (e.g., CHIR 99021)
causes an increase in activation of the canonical
transcriptional pathway of Wnt signaling [70]. Gsk-3β
heterozygous (+/-) mice display behaviors that resemble
wild type (WT) mice treated with lithium, a drug that is
used to treat bipolar disorder [71], demonstrating that
disruption of Wnt signaling leads to behavioral abnor-
malities. Furthermore, forebrain-specific deletion of Gsk-
3β in excitatory neurons leads to anxiolytic and pro-
social effects [72], suggesting that GSK-3β plays import-
ant roles in normal behavior. The most convincing evi-
dence that GSK3 and Wnt signaling may be involved in
developmental cognitive disorders is its role in Fragile X
syndrome (FXS), which is the most commonly inherited
form of intellectual disability and is linked to ASDs [73,
74]. Fragile X Mental Retardation Protein (FMRP) KO
mice, which is a FXS model, has been shown to possess
a dysregulation of GSK3β activity. Specifically, GSK-3β
protein and its activity is pathogenically elevated in FXS
models [75, 76], and pharmacological correction of this
enhanced activity using lithium or GSK3 inhibitors in
mice rescues neurobehavioral and brain morphological
abnormalities [77–82]. Furthermore, studies investigat-
ing FXS mice demonstrated that Wnt signaling is also
disrupted [83, 84]. Of course, GSK-3β has many down-
stream signaling targets, one of which is the Wnt signal-
ing pathway; demonstrating that modulation of GSK-3β
activity can have therapeutic effects beyond the treat-
ment of bipolar disorder.
Another well-studied gene in relation to ASD and psy-
chiatric disorders is disrupted in schizophrenia 1
(DISC1). While the genetic evidence linking DISC1 to
developmental cognitive disorders is not strong, the
multiple cellular and mouse models of Disc1 perturb-
ation has led to important findings linking Wnt signaling
to abnormal neurodevelopment. For example, a land-
mark study initially described DISC1 as an inhibitor of
GSK-3β, similar to the actions of lithium, demonstrating
that DISC1 positively regulates canonical Wnt signaling
[85], which has been followed up by other studies [86–
89]. Several follow-up studies on multiple mouse models
of Disc1 demonstrate that DISC1 perturbation causes
significant neurodevelopmental phenotypes, including
cognitive defects and psychiatric-like behavioral manifes-
tations [90–94].
There are other known regulators of Wnt signaling
that when disrupted leads to neurocognitive and neuro-
developmental phenotypes. A recent example is Ankyr-
inG (Ank3), which was found to possess a genome-wide
significant signal in bipolar disorder [95, 96]. Ank3 is a
scaffolding protein that localizes to the nodes of Ranvier
in mature neurons, important for the formation and
maintenance of the axon initial segment [95]. It has also
been shown to regulate glutamatergic synapse structure
and function through modulation of AMPAR-mediated
synaptic transmission and maintenance of dendritic
spine morphology [97]. Interestingly, Ank3 is a negative
regulator of canonical Wnt signaling during embryonic
neurogenesis in the mouse brain and functionally inter-
acts with DISC1 to regulate this process [46]. Ank3 het-
erozygous mice possess behavioral phenotypes such as
reduced anxiety and increased motivation for reward,
which can be corrected by modulating Wnt signaling
through GSK-3β [98], demonstrating the clinical involve-
ment of this pathway. In addition to Ank3, other recently
characterized genes in mice also support a role for Wnt
signaling in neurodevelopmental disorders. DIX domain
containing 1 (DIXDC1) is a positive regulator of Wnt
signaling and neurogenesis through binding to DISC1
[99] and a Dixdc1 KO mouse displayed behaviors associ-
ated with neuropsychiatric disorders such as abnormal
startle reflex and reduced social interaction [100]. The
behavioral phenotypes displayed by these mice could be
rescued through lithium or GSK3 inhibitor treatment
[101, 102].
There are three other Wnt signaling-related genes that
have been characterized in mice that lend further sup-
port to the involvement of Wnt signaling in develop-
mental cognitive disorders (see Fig. 1). The first is
adenomatous polyposis coli (APC), which is a critical
component of the destruction complex in the canonical
Wnt pathway and is important for neural plasticity,
learning, and memory in mice. A conditional Apc KO
mouse showed increased synaptic spine density, elevated
frequency of miniature excitatory postsynaptic potentials
(mEPSPs), enhanced long-term potentiation (LTP), and
ASD-like behaviors (e.g., repetitive behaviors and re-
duced social interest) [103]. Second, analysis of a
Prickle2 mouse model demonstrates its importance in
ASD-related neural circuits and behavior [104, 105].
Prickle2 is a postsynaptic protein that interacts with
PSD-95 and is part of the non-canonical Wnt signaling
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pathway [106]. The Prickle2 KO mouse has previously
been shown to be more sensitive to seizures and also
shows reduced dendrite branching, synapse number, and
postsynaptic density (PSD) size, as well as behavioral ab-
normalities (learning abnormalities, altered social inter-
action, and behavioral inflexibility). Although the
involvement of Prickle2 implicates non-canonical Wnt
signaling, the phenotypes associated with the KO mouse
demonstrate that multiple aspects of Wnt signaling (ca-
nonical and non-canonical) are important for the estab-
lishment of neural circuits that are disrupted in ASD.
While the studies on APC and Prickle2 do not directly
implicate abnormal Wnt signaling, we speculate that
these mice would have alterations in this pathway due to
the importance of these molecules in Wnt signaling in
neural cells. Third, a recent study identified that rare
missense variants in the Wnt1 gene discovered in ASD
patients show abnormal activation of the Wnt signaling
pathway, providing evidence that subtle changes to the
coding sequence of Wnt signaling molecules alter bio-
logical signaling [107]. Together, these studies indicate
that when analyzed using animal models, members of
the Wnt signaling pathway, which have no link to dis-
ease from human genetic studies, demonstrate how dis-
ruption of this core signaling pathway in the brain
results in developmental phenotypes consistent with hu-
man disease.
Targeting Wnt signaling in ASD/ID mouse models
In addition to animal models, there are two specific
drug-induced models that implicate Wnt signaling. The
first is valproic acid (VPA), which is thought to increase
the risk for ASD through exposure to a pregnant woman
during prenatal development [108]. The administration
of VPA to pregnant mice has long been used as a model
of ASD, as the offspring of these mice develop ASD-like
deficits in brain structure, neuronal signaling, and be-
havior [109]. VPA has many targets, but one of its better
characterized effects is the stimulation of the canonical
Wnt signaling pathway through modulation of histone
deacetylase and GSK3 [110–114], demonstrating that ab-
normal Wnt signaling likely plays an important role in
the pathogenicity of VPA. A second model that was re-
cently developed and more specifically implicates Wnt
signaling is exposure of pregnant mice to the compound,
XAV939, which is a tankyrase inhibitor, resulting in en-
hanced canonical Wnt signaling [115]. This leads to the
expansion of the intermediate progenitor cell population
in the developing cerebral cortex. The result of exposure
to XAV939 is an overpopulation of neurons in the cor-
tex, which disrupts the development and function of
dendrites and dendritic spines of excitatory neurons and
alters the distribution of interneurons. These mice ex-
hibit ASD-like behavioral abnormalities, implicating that
changes to canonical Wnt signaling during prenatal
brain development can have a profound impact on brain
size and function. These results suggest a causal rela-
tionship between abnormal modulation of Wnt signaling
during neurodevelopment and autism-like features [115].
Hope for ASD treatment using Wnt signaling modulators?
There is only one FDA approved for ASDs, which is
used to treat irritability associated with ASDs (risperi-
done, an antipsychotic medication), demonstrating the
urgent need to find new medications. Many of the medi-
cations used are “off-label” (e.g., antidepressants, anti-
convulsants, stimulants, and antianxiety medications)
and do not treat the core symptoms, and can have very
strong side effects. While these medications have mul-
tiple modes of molecular action, interestingly, many im-
pact Wnt signaling. For example, haloperidol (typical
antipsychotic medication) is known to inhibit dopamine
receptors, thereby increasing GSK3β inhibition through
Akt activation [116], which impacts downstream canon-
ical Wnt signaling [117, 118]. Selective serotonin re-
uptake inhibitors (SSRIs) (e.g., fluoxetine), which are
used to treat depression, potentially by increasing hippo-
campal neurogenesis in mice, have been shown to
antagonize canonical Wnt signaling, which causes a re-
duction in expression of the serotonin transporter
(SERT) in serotonergic raphe neurons through miR-16
[119, 120]. Additionally, lithium is a well-known treat-
ment for bipolar disorder, and one of its main activities
is inhibition of GSK-3β, which positively stimulates the
canonical Wnt pathway [121–123]. Stimulants such as
Methylphenidate (e.g., Ritalin) can function as a negative
regulator of the canonical pathway by activating GSK-3β
[124, 125]. In this regard, various GSK-3β inhibitors have
been used to rescue neurogenesis defects in mouse
models of psychiatric disorders and ASD, which also
stimulate canonical Wnt signaling pathways [69]. Taken
together, while it is important to be cautious of the mul-
tiple mechanisms of action of all of the classes of medi-
cations discussed here, it is intriguing to find that all of
them either directly or indirectly impact canonical Wnt
signaling in the brain to some degree. This suggests that
abnormal Wnt signaling likely plays a core role in the
disease pathogenesis of developmental cognitive disor-
ders, and restoring normal levels of this pathway with
medications could be an option for treatment.
Many times the medications tested in pilot clinical tri-
als for neurological disorders are failed drugs from can-
cer trials. There are many drugs developed and tested as
modulators of Wnt signaling in the cancer field that
could potentially be repurposed for developmental cog-
nitive disorders. In cases where a reduction in Wnt sig-
naling is thought to underlie the pathology of the
disorder, usage of compounds that elevated canonical
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Wnt signaling could be applied. An example of this is
GSK-3β inhibitors that have failed in cancer trials but
may be effective for ASDs and ID (e.g., Tideglusig, Clini-
calTrials.gov identifier: NCT02586935). In cases where
elevated Wnt signaling is thought to contribute to dis-
ease pathology, there are many potential options to in-
hibit canonical Wnt signaling using chemicals (Fig. 1)
that inhibit the interaction between β-catenin and its
targets (e.g., inhibiting β-catenin interaction with the
TCF factors), disheveled inhibitors (through targeting of
the PDZ domain which generally inhibit the Frizzled–
PDZ interaction), and tankyrase inhibitors (e.g.,
XAV939, which induces the stabilization of axin by inhi-
biting the poly (ADP)-ribosylating enzymes tankyrase 1
and tankyrase 2) [126]. These candidate compounds
may be of clinical use in cases where it is thought that
the genetic risk factor for ASD or ID causes elevated ca-
nonical Wnt signaling (e.g., potentially some individuals
with CHD8 mutations); however, even if these drugs
made it to the clinic, they would likely have to be deliv-
ered in utero, since embryonic brain development is
most affected by such genetic mutations, posing ethical
issues for pre-diagnosis therapies.
Conclusions
The goal towards better understanding and treating de-
velopmental cognitive disorders is a difficult road and
will require a multifaceted research and clinical ap-
proach to be successful. In this review, we present evi-
dence that one such signaling pathway that may be
central to disease pathogenesis and treatment is the Wnt
signaling network. Ongoing and future genetic studies
will need to determine the strength of association of this
pathway with disease; however, given the medications
and drugs that target this pathway currently available,
this presents an opportunity for new clinical trials in the
near future.
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